Foundayo vs. oral Wegovy: The similarities, the differences and what you need to know
The two oral GLP-1s will battle for market share. Foundayo is a small-molecule drug that can be taken with food. Some data suggest that oral Wegovy is slightly better at producing weight loss.
The FDA approval of Eli Lilly’s oral glucagon-like peptide 1 (GLP-1), Foundayo (orforglipron), yesterday set off what is bound to be a fierce fight for market share between Eli Lilly and Novo Nordisk and oral GLP-1, oral Wegovy. J.P. Morgan forecast earlier this year that by 2030, 30.3 million people in the U.S. will be taking on a GLP-1, up from 12.9 million this year. The convenience of the oral formulations, along with falling prices and expanding insurance coverage, are factors fueling prescriptions. Other companies and products are almost certainly going to enter the oral GLP-1 market, but for now it is a head-to-head contest between Foundayo and oral Wegovy. Here are 13 things to know about the two rivals.